Pfizer and Verastem in a pact for FAK inhibitor
09:32 EDT 13 Jul 2012 | Current Partnering
Verastem announced an agreement with Pfizer for the exclusive in-license of worldwide commercial rights for VS-6063 (formerly PF-04554878), a focal adhesion kinase (FAK) inhibitor that has completed a Phase 1 clinical study in advanced solid tumors. FAK is a non-receptor tyrosine kinase that regulates tumor cell proliferation and invasion. The targeted disruption of this pathway [...
Original Article: Pfizer and Verastem in a pact for FAK inhibitor
More From BioPortfolio on "Pfizer and Verastem in a pact for FAK inhibitor"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
